• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Siemens Healthineers and Hill-Rom team up to provide diabetes tools to primary care providers

May 7, 2018 By Sarah Faulkner

Hill-Rom, Siemens HealthineersSiemens Healthineers (NYSE:SI) and Hill-Rom (NYSE:HRC) inked a co-marketing agreement to provide an array of point-of-care diagnostic instruments for diabetes to primary healthcare providers in the U.S.

The offering is slated to include Siemens’ DCA Vantage Analyzer for HbA1c testing, the Clinitek Status+ Urine Chemistry Analyzer for kidney testing and Hill-Rom’s Welch Allyn RetinaVue Network and imaging tech for teleretinal exams.

The companies explained that they hope to offer a workflow that can reduce costs for healthcare systems and improve outcomes for patients. Siemens and Hill-Rom touted data showing that reducing a patient’s HbA1c level by 1% cuts their risk of kidney damage in half and reduces their risk of eye damage by 76%.

“A patient’s quality of life declines significantly when chronic diseases remain untreated, which is why testing for comorbidities is so important,” Mike Sampson, SVP of Siemen’s North America point-of-care diagnostics unit, said in prepared remarks.

“Our new commercial relationship with Hill-Rom will provide holistic, easy-to-implement solutions that aid in combating diabetes and related comorbidities while satisfying value-based quality care measures. With operator-friendly analyzers that generate lab-quality results in minutes and capabilities to integrate test results with electronic health records, physicians can make immediate treatment decisions and improve long-term outcomes,” Sampson added.

“Hill-Rom and Siemens Healthineers share a common vision to put patients on a better path to healthcare by providing solutions that allow our customers to transform care delivery with greater efficiency and effectiveness,” Alton Shader, president of Hill-Rom’s front line care business, said. “We have a tremendous opportunity in front of us and we are excited to activate this vision.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Diagnostics, Featured, Hospital Care, Wall Street Beat Tagged With: Hill-Rom Holdings, Siemens

IN CASE YOU MISSED IT

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS